Patents

Description

ANTICORPI UMANI, CARE LEAGĂ TNF ALPHA UMAN

Price not visible for this package

Interest:

Assignment

Publication info:

No.: RO123028

Date: 30.07.2010

Inventor(s):

SALFELD JOCHEN G [US]

ALLEN DEBORAH J [GB]

KAYMAKCALAN ZEHRA [US]

LABKOVSKY BORIS [US]

MANKOVICH JOHN A [US]

MCGUINNESS BRIAN T [GB]

ROBERTS ANDREW J [GB]

SAKORAFAS PAUL [US]

HOOGENBOOM HENDRICUS R J M [BE]

SCHOENHAUT DAVID [US]

VAUGHAN TRISTAN J [GB]

WHITE MICHAEL [US]

WILTON ALISON J [GB]

Applicant(s):
ABBOTT LAB BERMUDA LTD [BM]
Classification:
International patent classification (IPC):
A61K31/00; A61K31/40; A61K31/403; A61K31/404; A61K31/415; A61K31/4164; A61K31/4178; A61K31/505; A61K31/517; A61K31/52; A61K31/529; A61K31/57; A61K31/573; A61K31/675; A61K38/00; A61K38/04; A61K38/16; A61K39/39; A61K39/395; A61P1/00; A61P1/04; A61P1/16; A61P11/00; A61P11/16; A61P13/12; A61P17/00; A61P17/02; A61P19/02; A61P19/06; A61P25/00; A61P27/02; A61P29/02; A61P3/10; A61P31/00; A61P31/04; A61P31/12; A61P31/18; A61P33/06; A61P35/00; A61P35/04; A61P37/00; A61P37/02; A61P37/06; A61P37/08; A61P39/02; A61P7/00; A61P7/04; A61P9/00; A61P9/04; A61P9/10; C07K14/525; C07K16/24; C12N1/21; C12N15/09; C12N5/10; C12P21/08; G01N33/53; G01N33/543; G01N33/564; G01N33/576; G01N33/68
Cooperative patent classification (CPC):
A61K39/395 (KR); A61P1/00 (EP); A61P1/02 (EP); A61P1/04 (EP); A61P1/16 (EP); A61P11/00 (EP); A61P11/16 (EP); A61P13/12 (EP); A61P17/00 (EP); A61P17/02 (EP); A61P19/00 (EP); A61P19/02 (EP); A61P19/06 (EP); A61P19/08 (EP); A61P21/00 (EP); A61P25/00 (EP); A61P27/02 (EP); A61P29/00 (EP); A61P29/02 (EP); A61P3/04 (EP); A61P3/10 (EP); A61P31/00 (EP); A61P31/04 (EP); A61P31/12 (EP); A61P31/18 (EP); A61P31/20 (EP); A61P31/22 (EP); A61P33/06 (EP); A61P35/00 (EP); A61P35/04 (EP); A61P37/00 (EP); A61P37/02 (EP); A61P37/04 (EP); A61P37/06 (EP); A61P37/08 (EP); A61P39/02 (EP); A61P43/00 (EP); A61P7/00 (EP); A61P7/02 (EP); A61P7/04 (EP); A61P9/00 (EP); A61P9/04 (EP); A61P9/08 (EP); A61P9/10 (EP); C07K16/24 (KR); C07K16/241 (EP, US); C12N15/11 (KR); C12N15/64 (KR); C12N5/10 (KR); A61K2039/505 (EP, US); A61K38/00 (EP, US); C07K2317/21 (EP, US); C07K2317/56 (EP, US); C07K2317/565 (EP, US); Y02A50/30 (EP, US); Y10S424/81 (EP, US)
Application info:
No.: RO19200500050
Date: 10.02.1997
Priority number(s):
US19960599226 09.02.1996 ; US19960031476P 25.11.1996
Related patents:
ATE239041; AU2122997; AU722077; BG102755; BG107537; BG109311; BG110703; BG112042; BG64564; BG64776; BG66195; BG66509; BR9707379; BR9715219; BRPI9707379; BRPI9715219; CA2243459; CN100429232; CN101712720; CN102070715; CN103275221; CN1215407; CN1300173; CN1504752; CY2463; CZ247698; CZ292465; DE122004000003; DE122004000004; DE69721548; DK0929578; EP0929578; ES2198552; HK1019452; HK1066860; HK1125951; HK1125972; HK1214607; HK1214608; HK1214609; HK1214610; HU1500179; HU221984; HU228630; HU230048; HU230515; HU9901874; IL125697; JP2000507810; JP2003177130; JP2007045828; JP2010209119; JP2013091666; JP2014055150; JP2015108011; JP2016104798; JP3861118; JP4404181; JP4890997; JP5422501; JP5689902; JP5759526; JP5951056; KR100317188; KR19990082430; LU91062; MX336813; MX9806347; NL300143; NO20026202; NO2004002; NO20040052; NO20040154; NO2017038; NO316711; NO319955; NO320657; NO322755; NO983627; NZ331579; NZ512006; NZ536216; NZ562935; NZ576716; PL188192; PL193499; PL328411; PT929578; RO119831; RU2003120859; RU2005113954; RU2012102323; RU2270030; RU2458704; SI9720020; SK106298; SK284040; TR199801532; UA57726; UA82823; US2003092059; US2007249813; US2009155205; US2010040604; US2012258114; US2013115224; US2013330356; US2013330357; US6258562; US7223394; US7541031; US8206714; US8372400; US8753633; WO9729131
Description:

Invenţia se referă la un anticorp recombinant uman, care se leagă la factorul de necroză umană alpha (hTNF alpha ) care are afinitate pentru hTNFalpha, Kd = 10-8M sau mai mică, şi o constantă a vitezei Koff de 1 x 10-3s-1 sau mai mică, şi neutralizează activitatea in vitro şi in vivo, precum şi la un acid nucleic care îl codifică, celula gazdă care cuprinde un vector de expresie recombinant, precum şi la o compoziţie farmaceutică ce cuprinde anticorpul, administrată în tratamentul bolilor în care activitatea TNFalfa este dăunătoare.

Share this on:
Facebook Twitter/X LinkedIn Whatsapp Email